Zanling Zhang

Ms. Zanling Zhang


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2020 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
GZGuangting Zeng
Guangting Zeng
LWLinlin Wang
Linlin Wang
LSLihong Shi
Lihong Shi
HLHuilan Li
Huilan Li
MZMiaomiao Zhu
Miaomiao Zhu
ZZZanling Zhang
Zanling Zhang

28 January 2019 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
LSLihong Shi
Lihong Shi
MZMiaomiao Zhu
Miaomiao Zhu
HLHuilan Li
Huilan Li
ZWZhipeng Wen
Zhipeng Wen
XCXiaoping Chen
Xiaoping Chen
ZZZanling Zhang
Zanling Zhang

21 August 2020 in Nature Human Behaviour
Verified
Journal Article
Closed access
PDF file
GZGuangting Zeng
Guangting Zeng
LWLinlin Wang
Linlin Wang
ZZZanling Zhang
Zanling Zhang

12 April 2024 in Hematology
Verified
Journal Article
Open access
ZXZhiya Xu
Zhiya Xu
HLHuilan Li
Huilan Li
XYXinyi Yu
Xinyi Yu
JLJia Luo
Jia Luo
ZZZanling Zhang
Zanling Zhang
An association exists between immune checkpoint inhibitors and hemophagocytic lymphohistiocytosis (HLH). Therefore, the main objective of this study was to collect data on this rare but potentially life-threatening immune-related adverse reaction to identify the medications that cause it, the clinical characteristics, and effective treatments. Literature in English and Chinese on immune checkpoint inhibitors causing HLH published from August 2014 to March 2024 was analyzed. Immune checkpoint inhibitors, immunotherapy, anti-PD-1, PD-L1 inhibitors, HLH, hemophagocytic lymphohistiocytosis, hemophagocytic syndrome keywords were used to find the literature on China Knowledge Network, Wanfang, PubMed and Emabase Databases. Twenty-four studies were included, with a total of 27 patients (18 males and 9 females) with a mean age of 58 years (range 26-86). The mean time to the onset of symptoms was 10.3 weeks (7 days-14 months). The main clinical characteristics were fever, cytopenia, splenomegaly, methemoglobinemia, hypofibrinogenemia, and bone marrow biopsy showed phagocytosis. Twenty-two patients improved after the treatment with steroids, cytokine blocking therapy and symptomatic treatment, four patients died, and one patient was not described. HLH should be not underestimated as a potentially serious adverse effect of immune checkpoint inhibitors since appropriate treatments may save the life of patients.

11 October 2019 in Xenobiotica
Verified
Journal Article
Closed access
GZGuangting Zeng
Guangting Zeng
LSLihong Shi
Lihong Shi
HLHuilan Li
Huilan Li
LWLinlin Wang
Linlin Wang
MZMiaomiao Zhu
Miaomiao Zhu
ZZZanling Zhang
Zanling Zhang
1. Voriconazole is known to display highly variable pharmacokinetics affecting treatment efficacy and safety. This study aimed to identify the factors causing the variation of voriconazole concentration in patients with allogeneic hematopoietic stem cell transplantation. 2. The data of patients was collected, including clinical characteristics and voriconazole concentrations. A total of 5 single nucleotide polymorphisms of 3 candidate genes (CYP2C19, ABCC2, ABCG2) related to voriconazole metabolism were genotyped by MassArray method. The correlation between polymorphisms and voriconazole concentration was analyzed. 3. A total of 244 voriconazole concentrations of 43 patients were included in this study. The voriconazole concentration was significantly correlated with patients' total bile acid (P =0.001) and cyclosporin A (P < 0.001). The median concentration of the CYP2C19 normal metabolizers was remarkably lower than poor metabolizers (0.86 vs 2.27 μg/mL). The median concentration of ABCC2 rs2273697 GG genotype carriers was significantly higher than that of GA genotype carriers (P = 0.026). 4. The variability of voriconazole concentration is partially explained by total bile acid, metabolic types of CYP2C19. The voriconazole concentration of CYP2C19 normal metabolizers is likely to be lower than 1.0 μg/mL and thus at risk of infection due to inadequate treatment.

11 July 2022 in Immunopharmacology and Immunotoxicology
Verified
Journal Article
Closed access
JLJianqiang Li
Jianqiang Li
LWLinlin Wang
Linlin Wang
GZGuangting Zeng
Guangting Zeng
HLHuilan Li
Huilan Li
JLJia Luo
Jia Luo
ZZZanling Zhang
Zanling Zhang
Rheumatoid arthritis (RA) is mainly characterized by synovial hyperplasia, angiogenesis, inflammatory cells infiltration. Chymotrypsin is a proteolytic enzyme with anti-inflammatory effects. The cu...